Hormonal
Daily oral administration of MK-677 (10-25 mg) to healthy elderly subjects (64-81 years) significantly increases 24-hour mean GH concentrations and serum IGF-I levels in a dose-dependent manner by enhancing the amplitude of pulsatile GH secretion without changing pulse frequency.
For healthy older adults, taking 10-25 mg of oral MK-677 daily for 2-4 weeks significantly boosts Growth Hormone and IGF-1 levels, bringing them closer to young adult ranges. This is achieved by increasing the size of natural GH pulses rather than creating constant high levels. While it may slightly raise fasting blood glucose, it was generally well-tolerated in this short-term study, offering a non-injectable alternative to GH therapy.
Oral administration of MK-677 produced dose-dependent increases in mean 24-h GH concentrations... The highest dose (25 mg/day) increased IGF-I concentrations 55 +/- 10% at 2 weeks and 88 +/- 16% at 4 weeks... MK-677 treatment enhanced pulsatile GH release rather than a sustained increase in serum GH concentrations... increased the height of GH pulses and interpeak nadir GH concentrations, without any change in the number of GH pulses.
Why this rating
Randomized, double-blind, placebo-controlled trial with multiple doses and rigorous deconvolution analysis of GH pulses.
Source
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Ian Chapman et al. · The Journal of Clinical Endocrinology & Metabolism · 1996
DOI 10.1210/jcem.81.12.8954023
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →